Waxman reiterates scientific review request

Share this article:
Incoming Committee on Government Reform Chair Rep. Henry Waxman (D-CA) reiterated his request that the FDA conduct a thorough scientific review of phenylephrine's effectiveness at 10 mg as used in reformulated OTC decongestants, citing a DTC ad for Schering-Plough's Claritin-D indicating the company will not reformulate it.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Pharmaceutical

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.